NextCure, Inc. Reports Board Changes and Executive Compensation Updates

TL;DR

NextCure board shakeup and exec pay changes filed. Watch for new leadership direction.

AI Summary

On August 21, 2025, NextCure, Inc. reported a change in its board of directors and executive compensation arrangements. The filing indicates the departure of certain directors and the election of new ones, alongside updates to compensatory arrangements for its officers. Specific details regarding the individuals involved and the financial implications of these changes are outlined within the report.

Why It Matters

Changes in a company's board and executive compensation can signal shifts in strategy, governance, or financial outlook, impacting investor confidence and future performance.

Risk Assessment

Risk Level: medium — Changes in board composition and executive compensation can indicate internal shifts that may affect company strategy and performance.

Key Players & Entities

• NextCure, Inc. (company) — Registrant
• August 21, 2025 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• 47-5231247 (ein) — IRS Employer Identification No.
• Beltsville, Maryland (location) — Principal executive offices
• 240-399-4900 (phone_number) — Registrant's telephone number

FAQ

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value per share NXTC Nasdaq Glo

Filing Documents

• nxtc-20250821x8k.htm (8-K) — 41KB
• 0001558370-25-011752.txt ( ) — 159KB
• nxtc-20250821.xsd (EX-101.SCH) — 4KB
• nxtc-20250821_def.xml (EX-101.DEF) — 3KB
• nxtc-20250821_lab.xml (EX-101.LAB) — 17KB
• nxtc-20250821_pre.xml (EX-101.PRE) — 11KB
• nxtc-20250821x8k_htm.xml (XML) — 5KB

From the Filing

NextCure, Inc._August 21, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 21, 2025 NextCure, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38905 (Commission File Number) 47-5231247 (IRS Employer Identification No.) 9000 Virginia Manor Road , Suite 200 Beltsville , Maryland 20705 (Address of principal (Zip Code) executive offices) Registrant's telephone number, including area code: ( 240 ) 399-4900 (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.001 par value per share NXTC Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On August 21, 2025, Solomon Langermann, Ph.D., resigned from his position as Chief Scientific Officer of NextCure, Inc. (the "Company"), effective September 1, 2025. Dr. Langermann's decision to resign was not the result of any disagreement with the Company or any matter relating to the operations, policies or practices of the Company. The Company and its Board of Directors thank Dr. Langermann for his scientific leadership at the Company and are grateful for his many valuable contributions during his tenure . SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. November Dated: August 25, 2025 NEXTCURE, INC. By: /s/ Steven P. Cobourn Name: Steven P. Cobourn Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR